4.08
0.24 (6.25%)
| Previous Close | 3.84 |
| Open | 3.80 |
| Volume | 1,251,591 |
| Avg. Volume (3M) | 675,423 |
| Market Cap | 130,621,608 |
| Price / Sales | 0.270 |
| Price / Book | 0.940 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2025 - 10 Feb 2025 |
| Profit Margin | -19.80% |
| Operating Margin (TTM) | -17.29% |
| Diluted EPS (TTM) | -4.19 |
| Quarterly Revenue Growth (YOY) | -32.80% |
| Total Debt/Equity (MRQ) | 236.01% |
| Current Ratio (MRQ) | 0.310 |
| Operating Cash Flow (TTM) | 14.33 M |
| Levered Free Cash Flow (TTM) | 26.63 M |
| Return on Assets (TTM) | -2.91% |
| Return on Equity (TTM) | -43.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Inotiv, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 13.48% |
| % Held by Institutions | 13.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kpp Advisory Services Llc | 30 Sep 2024 | 237,718 |
| Fi3 Financial Advisors, Llc | 30 Sep 2024 | 80,710 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Dec 2024 | Announcement | Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million |
| 23 Dec 2024 | Announcement | Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million |
| 18 Dec 2024 | Announcement | Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares |
| 17 Dec 2024 | Announcement | Inotiv, Inc. Launches Proposed Public Offering of Common Shares |
| 03 Dec 2024 | Announcement | Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update |
| 21 Nov 2024 | Announcement | Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
| 20 Nov 2024 | Announcement | Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 |
| 07 Nov 2024 | Announcement | Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |